Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
Top Cited Papers
Open Access
- 19 November 2013
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 95 (4), 423-431
- https://doi.org/10.1038/clpt.2013.229
Abstract
Since September 2010, more than 10,000 patients have undergone preemptive, panel‐based pharmacogenomic testing through the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program. Analysis of the genetic data from the first 9,589 individuals reveals that the frequency of genetic variants is concordant with published allele frequencies. Based on five currently implemented drug–gene interactions, the multiplexed test identified one or more actionable variants in 91% of the genotyped patients and in 96% of African American patients. Using medication exposure data from electronic medical records, we compared a theoretical “reactive,” prescription‐triggered, serial single‐gene testing strategy with our preemptive, multiplexed genotyping approach. Reactive genotyping would have generated 14,656 genetic tests. These data highlight three advantages of preemptive genotyping: (i) the vast majority of patients carry at least one pharmacogenetic variant; (ii) data are available at the point of care; and (iii) there is a substantial reduction in testing burden compared with a reactive strategy. Clinical Pharmacology & Therapeutics (2014); 95 4, 423–431. doi:10.1038/clpt.2013.229Keywords
This publication has 37 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol DosingClinical Pharmacology & Therapeutics, 2012
- The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced MyopathyClinical Pharmacology & Therapeutics, 2012
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT ProjectClinical Pharmacology & Therapeutics, 2012
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir DosingClinical Pharmacology & Therapeutics, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology & Therapeutics, 2011
- UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-AmericansMutation research. Reviews in mutation research, 2008
- Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClinical Pharmacology & Therapeutics, 2005